Financial News

Recent Quotes
My Watchlist
Indicators
Motherlode Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adamis Pharmaceuticl (NQ: ADMP )

1.120 USD +0.010 (+0.90%)
Official Closing Price Updated: 7:59 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Adamis Pharmaceuticl

< Previous 1 2 3 4 5 Next >
Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
From GlobeNewswire News Releases
Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate
From GlobeNewswire News Releases
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
From GlobeNewswire News Releases
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients
From GlobeNewswire News Releases
Adamis Pharmaceuticals Provides Update On Its US Compounding Business
From GlobeNewswire News Releases
Immunotherapy Using Immune-Checkpoint Inhibitors (ICI) Modulators Are Revolutionizing Oncology Industry
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Immunotherapy Using Immune-Checkpoint Inhibitors (ICI) Modulators Are Revolutionizing Oncology Industry
Financialnewsmedia.com News Commentary 
From PR Newswire
SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products
From GlobeNewswire News Releases
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19
From GlobeNewswire News Releases
Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response Letter
From GlobeNewswire News Releases
Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI
From GlobeNewswire News Releases
Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
From GlobeNewswire News Releases
Adamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call and Business Update
From GlobeNewswire News Releases
Thinking about buying stock in DouYu, Adamis Pharmaceuticals, Altimmune, FuelCell Energy, or Ovid Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for DOYU, ADMP, ALT, FCEL, and OVID. 
From PR Newswire
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Thinking about buying stock in iBio Inc, Virgin Galactic, Sorrento Therapeutics, Adamis Pharmaceuticals, or Plug Power?
InvestorsObserver issues critical PriceWatch Alerts for IBIO, SPCE, SRNE, ADMP, and PLUG. 
From PR Newswire
Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders
From GlobeNewswire News Releases
Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders and Proposals
From GlobeNewswire News Releases
Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders
From GlobeNewswire News Releases
Adamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update
From GlobeNewswire News Releases
Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19
From GlobeNewswire News Releases
Adamis Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
From GlobeNewswire News Releases
Adamis Pharmaceuticals Provides Update on SYMJEPI Products
From GlobeNewswire News Releases
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose
From GlobeNewswire News Releases
Thinking about buying stock in TOP Ships, Hertz, Biocept, Edesa Biotech, or Adamis Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for TOPS, HTZ, BIOC, EDSA, and ADMP. 
From PR Newswire
Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19
From GlobeNewswire News Releases
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback